部分的なワクチンでもエボラ流行を抑制できる可能性をモデルが示す（Model shows partial vaccine could contain Ebola outbreak）

2026-09-11

2026-09-02 スタンフォード大学

スタンフォード大学の研究者らは、エボラ出血熱の流行時に、全人口をワクチン接種しなくても部分的なワクチン接種によって流行を封じ込められる可能性を数理モデルで示した。研究では、2025年にウガンダで発生したエボラ流行をモデル化し、ワクチンの供給が限られる状況で、誰をどの順序で接種することが最も効果的かを分析した。その結果、感染者と接触した人を優先する「リングワクチン接種」を基本としながら、接触者が多く追跡困難な地域では、人口の約10％を対象とする地域的な一斉接種を組み合わせることで、流行抑制効果を高められることが示された。特に、ワクチン接種率だけでなく、接触者追跡の速度や精度、地域ごとの感染状況を考慮して接種戦略を切り替えることが重要とされた。研究は、ワクチン不足時にも限られた資源を効率的に配分し、感染拡大を抑えるための意思決定支援に活用できる可能性を示している。

＜関連情報＞

ブンディブギョウイルスのアウトブレイク対応における環状ワクチン接種と地域ワクチン接種：確率的ネットワークモデリング研究 Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study

Prof Jason R Andrews, MD ∙ Placide K Mbala, PhD ∙ Patrick K Mukadi, PhD ∙ Jason Kindrachuk, PhD ∙ Nicole A Hoff, PhD ∙ Prof Anne W Rimoin, PhD ∙ et al.
The Lancet Infectious Diseases Published: September 2, 2026
DOI:https://doi.org/10.1016/S1473-3099(26)00464-0

Summary

Background
Vaccination with rVSV-ZEBOV is highly effective against Ebola virus, but protection against Bundibugyo virus (BDBV) is unproven. We evaluated the relative population impact and dose efficiency of a partially cross-protective hypothetical vaccine under operationally realistic constraints during a BDBV outbreak.

Methods
We developed a stochastic transmission model on a clustered household–community contact network with empirically realistic local structure, calibrated to 2026 DR Congo BDBV outbreak data. Time-varying effective reproduction numbers were estimated using a Bayesian renewal model. We evaluated case detection, isolation, contact tracing, reactive ring vaccination (Ring 1: direct contacts of the index case; Ring 2: contacts of contacts), and community vaccination (20–80% coverage). Base-case vaccine effectiveness was 45% and included post-exposure protection against disease and mortality. Primary outcomes were mortality and incidence reductions, total doses, and dose efficiency (doses per death averted) over 90 days, evaluated in a probabilistic sensitivity analysis with 10 000 matched stochastic replicates per strategy.

Findings
Compared with base operations alone (30% detection, 30% tracing), enhanced operations alone (70% detection, 80% tracing) reduced expected mortality by 81·6% (95% uncertainty interval 73·1–87·7). Reactive Ring 2 vaccination under base operations reduced mortality by 24·6% (18·0–29·6), requiring 35·1 doses per death averted. Added to enhanced operations, Ring 2 vaccination reduced mortality by 83·6% overall (76·4–89·0), an incremental benefit of 10·5% (6·2–15·6) beyond enhanced operations alone. Community vaccination at 20%, 40%, 60%, and 80% coverage reduced mortality by 44·7% (34·8–52·5), 67·4% (56·2–74·3), 79·8% (70·4–85·3), and 86·6% (79·2–90·4), respectively, requiring 53·8–111·4 doses per death averted.

Interpretation
Strengthened case finding, contact tracing, and isolation averted most deaths even without vaccination. Once these operations were strong, reactive ring vaccination added a modest further benefit, whereas rapid community vaccination produced the largest reductions in simulated scenarios but required substantially more doses. A partially protective BDBV vaccine’s population-level value will depend principally on rapid, broad delivery.

Funding
Canadian Institutes of Health Research.

Translation
For the French translation of the abstract see Supplementary Materials section.